STTK Stock Analysis: Buy, Sell, or Hold?
STTK - Shattuck Labs, Inc. Common Stock
$3.85
-0.02 (-0.52%)
▼
5d:
-5.17%
30d:
+5.48%
90d:
+100.52%
HOLD
LOW Confidence
Last Updated: February 2, 2026
Earnings: Mar 26, 2026
Get Alerted When STTK Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: STTK shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: STTK shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: STTK is currently trading at $3.85, which is considered slightly low relative to its 30-day fair value range of $3.75 to $4.58.
Technical Outlook: Technically, STTK is in a strong uptrend. The price is currently testing key support at $3.82. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $7.25 (+88.3%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, STTK is in a strong uptrend. The price is currently testing key support at $3.82. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $7.25 (+88.3%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Fair Price Range
$3.75 -
$4.58
Company Quality Score
57/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
86.2%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 0th percentile)
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 88.3% below Wall St target ($7.25)
- CAUTION: Recommendation downgraded due to -5.2% 5-day decline
Fair Price Analysis
30-Day Fair Range
$3.75 -
$4.58
Current vs Fair Value
SLIGHTLY LOW
Expected Move (7 Days)
±$0.57
(14.7%)
Support & Resistance Levels
Support Level
$3.82
Resistance Level
$4.65
Current Trend
Strong Uptrend
Fundamental Context
Forward P/E (Next Year Est.)
-7.52
Wall Street Target
$7.25
(+88.3%)
Revenue Growth (YoY)
-66.6%
Last updated: February 03, 2026 12:06 AM ET
Data refreshes hourly during market hours. Next update: 1:06 AM
Data refreshes hourly during market hours. Next update: 1:06 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is STTK showing a specific setup today?
Insider Activity (6 Months)
2
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
Mona Ashiya
BUY
6306127 shares
2025-08-25
Orbimed Advisors Llc
BUY
6306127 shares
2025-08-25
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$66 | 58 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$112 | 57 HOLD |
|
RNA
Avidity Biosciences Inc |
STRONG BUY
15 analysts |
$75 | 61 BUY |
|
DNTH
Dianthus Therapeutics In… |
STRONG BUY
12 analysts |
$71 | 60 HOLD |
|
TVTX
Travere Therapeutics Inc |
STRONG BUY
15 analysts |
$42 | 56 HOLD |
